PIK3CB and pancreatic ductal adenocarcinoma: Research showed that over 90% of pancreatic ductal adenocarcinoma (PDAC) cases harboured KRAS mutations, which activated PI3K/AKT signalling pathways, key drivers of tumour proliferation, drug resistance and metastasis34.